Apigenin causes G2/M arrest associated with the modulation of p21Cip1 and Cdc2 and activates p53-dependent apoptosis pathway in human breast cancer SK-BR-3 cells

Journal of Nutritional Biochemistry

Volumn 20, Issue 4, 2009, Pages 285-290

  Choi, Eun Jeong ^a   Kim, Gun Hee ^a  

^a Duksung Women's University   (South Korea)

Author keywords

Apigenin; Apoptosis; CDK1; G2 M phase; p53; SK BR 3 cells

Indexed keywords

APIGENIN; CYCLIN D; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; PROTEIN P53;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL;

APIGENIN; APOPTOSIS; BREAST NEOPLASMS; CDC2 PROTEIN KINASE; CELL DIVISION; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; G2 PHASE; HUMANS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 61749103821     PISSN: 09552863     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2008.03.005     Document Type: Article

References (36)

1. Sun S.Y., Hail Jr. N., and Lotan R. Apoptosis as a novel target for cancer chemoprevention. J Natl Cancer Inst 96 (2004) 662-672
2. Zhang Z., Li M., Rayburn E.R., Hill D.L., Zhang R., and Wang H. Oncogenes as novel targets for cancer therapy (part IV): regulators of the cell cycle and apoptosis. Am J Pharmacogenomics 5 (2005) 397-407
3. Fesik S.W. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 5 (2005) 876-885
4. Yu J., and Zhang L. Apoptosis in human cancer cells. Curr Opin Oncol 16 (2004) 19-24
5. Miean K.H., and Mohamed S. Flavonoid (myricetin, quercetin, kaempferol, luteolin, and apigenin) content of edible tropical plants. J Agric Food Chem 49 (2001) 3106-3112
6. Soares R., and Azevedo I. Apigenin: is it a pro- or anti-inflammatory agent?. Am J Pathol 168 (2006) 1762-1763
7. Fuchs J., and Milbradt R. Skin anti-inflammatory activity of apigenin-7-glucoside in rats. Arzneimittelforschung 43 (1993) 370-372
8. Singh J.P., Selvendiran K., Banu S.M., and Padmavathi R. Protective role of Apigenin on the status of lipid peroxidation and antioxidant defense against hepatocarcinogenesis in Wistar albino rats. Phytomedicine 11 (2004) 309-314
9. Romanova D., Vachalkova A., Cipak L., Ovesna Z., and Rauko P. Study of antioxidant effect of apigenin, luteolin and quercetin by DNA protective method. Neoplasma 48 (2001) 104-107
10. Bektic J., Guggenberger R., Spengler B., Christiffel V., Pelzer A., Berger A.P., et al. The flavonoid apigenin inhibits the proliferation of prostatic stromal cells via the MAPK-pathway and cell-cycle arrest in G1/S. Maturitas 55s (2006) s37-s46
11. Lindenmeyer F., Li H., Menashi S., Soria C., and Lu H. Apigenin acts on the tumor cell invasion process and regulates protease production. Nutr Cancer 39 (2001) 139-147
12. Gupta S., Afag F., and Mukhtar H. Selective growth-inhibitory, cell-cycle deregulatory and apoptotic response of apigenin in normal versus human prostate carcinoma cells. Biochem Biophys Res Commun 287 (2001) 914-920
13. Chiang L.C., Ng L.T., Lin I.C., Kuo P.L., and Lin C.C. Anti-proliferative effect of apigenin and its apoptotic induction in human Hep G2 cells. Cancer Lett 237 (2006) 207-214
14. Czeczot H., Tuek B., Kusztelak J., Szymczyk T., Dobrowolska B., Glinkowska G., et al. Isolation and studies of the mutagenic activity in the Ames test of flavonoids naturally occurring in medical herbs. Mutat Res 240 (1990) 209-216
15. Yin F., Giuliano A.E., Law R.E., and Van Herle A.J. Apigenin inhibits growth and induces G2/M arrest by modulating cyclin-CDK regulators and ERK MAP kinase activation in breast carcinoma cells. Anticancer Res 21 (2001) 413-420
16. Ren W., Oiao Z., Wang H., Zhu L., and Zhang L. Flavonoids: promising anticancer agents. Med Res Rev 23 (2003) 519-534
17. Lopez-Lazaro M. Flavonoids as anticancer agents: structure-activity relationship study. Curr Med Chem Anticancer Agents 2 (2002) 691-714
18. Singh R.P., and Agarwal R. Natural flavonoids targeting deregulated cell cycle progression in cancer cells. Curr Drug Targets 7 (2006) 345-354
19. Breinholt V., Hossaini A., Svendsen G.W., Brouwer C., and Nielsen E. Estrogenic activity of flavonoids in mice. The importance of estrogen receptor distribution, metabolism and bioavailability. Food Chem Toxicol 38 (2000) 555-564
20. Wang W., Heideman L., Chung C.S., Pelling J.C., Koehler K.J., and Birt D.F. Cell-cycle arrest at G2/M and growth inhibition by apigenin in human colon carcinoma cell lines. Mol Carcinog 28 (2000) 102-110
21. Ford H.L., Landesman-Bollag E., Dacwag C.S., Stukenberg P.T., Pardee A.B., and Seldin D.C. Cell cycle-regulated phosphorylation of the human SIX1 homeodomain protein. J Biol Chem 275 (2000) 22245-22254
22. Birt D.F., Hendrich S., and Wang W. Dietary agents in cancer prevention: flavonoids and isoflavonoids. Pharmacol Ther 90 (2001) 157-177
23. Lepley D.M., Li B., Birt D.F., and Pelling J.C. The chemopreventive flavonoid apigenin induces G2/M arrest in keratinocytes. Carcinogenesis 17 (1996) 2367-2375
24. Morla A.O., Draetta G., Beach D., and Wang J.Y. Reversible tyrosine phosphorylation of cdc2: dephosphorylation accompanies activation during entry into mitosis. Cell 58 (1989) 193-203
25. Jessus C., and Beach D. Oscillation of MPF is accompanied by periodic association between cdc25 and cdc2-cyclin B. Cell 68 (1992) 323-332
26. Lee J.W., Moon M.J., Min H.Y., Chung H.J., Park E.J., Park H.J., et al. Induction of apoptosis by a novel indirubin-5-nitro-3¢-monoxime, a CDK inhibitor, in human lung cancer cells. Bioorg Med Chem Lett 15 (2005) 3948-3952
27. Agrawal S., Agarwal M.L., Chatterjee-Kishore M., Stark G.R., and Chisolm G.M. Stat1-dependent, p53-independent expression of p21(waf1) modulates oxysterol-induced apoptosis. Mol Cell Biol 22 (2005) 1981-1992
28. Mahyar-Roemer M., and Roemer K. p21 Waf1/Cip1 can protect human colon carcinoma cells against p53-dependent and p53-independent apoptosis induced by natural chemopreventive and therapeutic agents. Oncogene 20 (2001) 3387-3398
29. Kachnic L.A., Wu B., Wunsch H., MeKeel K.L., DeFrank J.S., Tang W., et al. The ability of p53 to activate downstream genes p21(WAF1/cip1) and MDM2, and cell cycle arrest following DNA damage is delayed and attenuated in scid cells deficient in the DNA-dependent protein kinase. J Biol Chem 274 (1999) 13111-13117
30. Agarwal M.L., Agarwal A., Taylor W.R., and Stark G.R. p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc Natl Acad Sci U S A 92 (1995) 8493-8497
31. Park M., Chae H.D., Yun J., Jung M., Kim Y.S., Kim S.H., et al. Constitutive activation of cyclin B1-associated cdc2 kinase overrides p53-mediated G2-M arrest. Cancer Res 60 (2000) 542-545
32. Lepik D., Jaks V., Kadaja L., Varv S., and Maimet T. Electroporation and carrier DNA cause p53 activation, cell cycle arrest, and apoptosis. Anal Biochem 318 (2003) 52-59
33. Parker M.A., Anderson J.K., Corliss D.A., Abraria V.E., Sidman R.L., Park K.I., et al. Expression profile of an operationally-defined neural stem cell clone. Exp Neurol 194 (2005) 320-332
34. Fang J., Xia C., Cao Z., Zheng J.Z., Reed E., and Jiang B.H. Apigenin inhibits VEGF and HIF-1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways. FASEB J 19 (2005) 342-353
35. Fang J., Zhou Q., Liu L.Z., Xia C., Hu X., Shi X., et al. Apigenin inhibits tumor angiogenesis through decreasing HIF-1alpha and VEGF expression. Carcinogenesis 28 (2007) 858-864
36. Simons A.L., Renouf M., Hendrich S., and Murphy P.A. Human gut microbial degradation of flavonoids: structure-function relationships. J Agric Food Chem 53 (2005) 4258-4263